WALTHAM, Mass., November 12, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing […]
read moreWALTHAM, Mass., November 5, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing […]
read morePatent to Provide Broad Coverage for EyeGate II® Delivery System with Pre-filled Drug Applicator Also, Patent Covering Proprietary Dexamethasone Phosphate Pharmaceutical Formulation Granted WALTHAM, Mass., […]
read moreEyeGate will be hosting a cocktail party during AAO Annual Meeting.We would love you to stop by. Please click the link below to RSVP or […]
read moreClick here for the complete article.[…]
read moreWALTHAM, Mass., Sept. 1, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing […]
read moreWALTHAM, Mass., August 5, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and […]
read moreWALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (EYEG) (NASDAQ:EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing […]
read morePatent to Provide Broad Coverage for Steroid Delivered Via Ocular Iontophoresis WALTHAM, Mass., July 24, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc.(OTCQB:EYEG) (“EyeGate” or the […]
read moreFirst Clinical Trial Evaluating EyeGate(R) II Delivery System in Posterior of Eye WALTHAM, Mass., July 14, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (EYEG) (“EyeGate” […]
read more